Clinical Trials Browser

Phase 3 × Urogenital Neoplasms × Genitourinary × Clear all

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT06717711 2024-12-05

RCT_LiESWT

Phase 3 Recruiting

158 enrolled

Genitourinary

Prostatic Neoplasms, Urogenital Neoplasms

NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Phase 3 Withdrawn

Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT01310894 2019-07-11

PCM301

Phase 3 Completed

413 enrolled

Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Phase 3 Terminated

1 enrolled 5 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT00631371 2016-04-27

INTORACT

Phase 3 Completed

791 enrolled 11 charts

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Urogenital Neoplasms

NCT02254915 2015-04-01

SHTC-EUROPE-1

Phase 3 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Clinical Trials

CYCLONE 3

RCT_LiESWT

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

PCM301

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

INTORACT

SHTC-EUROPE-1